Lymphangioleiomyomatosis

"Lymphangioleiomyomatosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).

Descriptor ID	D018192
MeSH Number(s)	C04.557.375.460.465 C04.557.450.692.500 C15.604.515.562.465 C20.683.515.710.465
Concept/Terms	Lymphangioleiomyomatosis Lymphangioleiomyomatosis Lymphangioleiomyomatoses Lymphangiomyomatosis Lymphangiomyomatoses

Below are MeSH descriptors whose meaning is more general than "Lymphangioleiomyomatosis".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Lymphatic Vessel Tumors [C04.557.375]
Lymphangiomyoma [C04.557.375.460]
Lymphangioleiomyomatosis [C04.557.375.460.465]
Neoplasms, Connective and Soft Tissue [C04.557.450]
Perivascular Epithelioid Cell Neoplasms [C04.557.450.692]
Lymphangioleiomyomatosis [C04.557.450.692.500]
Hemic and Lymphatic Diseases [C15]
Lymphatic Diseases [C15.604]
Lymphoproliferative Disorders [C15.604.515]
Lymphangiomyoma [C15.604.515.562]
Lymphangioleiomyomatosis [C15.604.515.562.465]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Lymphoproliferative Disorders [C20.683.515]
Lymphangiomyoma [C20.683.515.710]
Lymphangioleiomyomatosis [C20.683.515.710.465]

Below are MeSH descriptors whose meaning is related to "Lymphangioleiomyomatosis".

Below are MeSH descriptors whose meaning is more specific than "Lymphangioleiomyomatosis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lymphangioleiomyomatosis" by people in this website by year, and whether "Lymphangioleiomyomatosis" was a major or minor topic of these publications.

Bar chart showing 22 publications over 15 distinct years, with a maximum of 3 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
2002	1	0	1
2003	1	1	2
2004	1	0	1
2006	0	1	1
2009	1	0	1
2010	2	0	2
2011	1	0	1
2014	1	0	1
2015	2	1	3
2017	2	0	2
2018	1	0	1
2019	2	0	2
2020	1	0	1
2021	2	0	2

Below are the most recent publications written about "Lymphangioleiomyomatosis" by people in Profiles.

Ng J, Pacheco-Rodriguez G, Begley L, Huang YJ, Poli S, Perrella MA, Rosas IO, Moss J, El-Chemaly S. The lung microbiome in end-stage Lymphangioleiomyomatosis. Respir Res. 2021 Oct 26; 22(1):277.

View in: PubMed
Wang MX, Segaran N, Bhalla S, Pickhardt PJ, Lubner MG, Katabathina VS, Ganeshan D. Tuberous Sclerosis: Current Update. Radiographics. 2021 Nov-Dec; 41(7):1992-2010.

View in: PubMed
El-Chemaly S, Taveira-DaSilva A, Bagwe S, Klonowska K, Machado T, Lamattina AM, Goldberg HJ, Jones AM, Julien-Williams P, Maurer R, Rosas IO, Henske EP, Moss J, Kwiatkowski DJ. Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. Eur Respir J. 2020 05; 55(5).

View in: PubMed
Tang Y, El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Bagwe S, Rosas IO, Moss J, Priolo C, Henske EP. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells. Chest. 2019 12; 156(6):1137-1148.

View in: PubMed
Lamattina AM, Poli S, Kidambi P, Bagwe S, Courtwright A, Louis PH, Shrestha S, Stump B, Goldberg HJ, Thiele EA, Rosas I, Henske EP, El-Chemaly S. Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis. Orphanet J Rare Dis. 2019 03 29; 14(1):72.

View in: PubMed
Lamattina AM, Taveira-Dasilva A, Goldberg HJ, Bagwe S, Cui Y, Rosas IO, Moss J, Henske EP, El-Chemaly S. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Chest. 2018 11; 154(5):1070-1082.

View in: PubMed
Cui Y, Steagall WK, Lamattina AM, Pacheco-Rodriguez G, Stylianou M, Kidambi P, Stump B, Golzarri F, Rosas IO, Priolo C, Henske EP, Moss J, El-Chemaly S. Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res. 2017 03 15; 77(6):1492-1502.

View in: PubMed
El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Peters E, Haughey M, Bienfang D, Jones AM, Julien-Williams P, Cui Y, Villalba JA, Bagwe S, Maurer R, Rosas IO, Moss J, Henske EP. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest. 2017 06; 151(6):1302-1310.

View in: PubMed
Belloli EA, Martinez FJ, Flaherty KR. Update in Interstitial Lung Disease 2014. Am J Respir Crit Care Med. 2015 Sep 01; 192(5):538-43.

View in: PubMed
Rasmussen JC, Fife CE, Sevick-Muraca EM. Near-Infrared Fluorescence Lymphatic Imaging in Lymphangiomatosis. Lymphat Res Biol. 2015 Sep; 13(3):195-201.

View in: PubMed

People

Explore

Similar Concepts

Top Journals